Targovax, a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, has appointed Erik Digman Wiklund as thecCompany’s new Chief Financial Officer, and will take up this role in April 2017. The previous CFO, Oystein Soug, was appointed as Targovax’s CEO on 2 November 2016.
Erik joins from the nutraceutical company Aker Biomarine Antarctic AS, where he held the position as Director of Product Innovation. Prior to joining Aker Biomarine, Erik worked for Norwegian cancer biotechnology company Algeta ASA, and also has management consulting experience from the Pharma & Health Care practice of McKinsey & Company. Erik holds a PhD in Molecular Biology from Aarhus University, Denmark, and the Garvan Institute of Medical Research in Sydney, Australia.
